GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Systemic Lupus Erythematosus overview

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that can affect various organs and tissues, including the skin, joints, kidneys, heart, lungs, and brain. It is characterized by the production of autoantibodies that attack the body’s own cells and tissues, leading to inflammation and tissue damage. SLE presents with a wide range of symptoms, such as fatigue, joint pain, skin rashes (especially the characteristic butterfly rash on the face), fever, and organ dysfunction. The exact cause of SLE is unknown, but genetic predisposition, hormonal factors, and environmental triggers play roles. Treatment involves medications to manage symptoms and suppress the immune system, along with lifestyle modifications and regular monitoring to prevent flares and complications.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

G lobalDat a, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.